Vabysmo (Faricimab)

Vabysmo is a medicine used to treat eye diseases like wet macular degeneration and swelling in the retina from diabetes or a blocked vein. A doctor gives it as a shot into the eye, often every one to four months. It works by blocking two signals that make leaky, unhealthy blood vessels grow in the back of the eye.

Brand names:Vabysmo
Medication

What people taking Vabysmo (Faricimab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Vabysmo (Faricimab) for Wet Macular Degeneration?

NameHow it went

About Vabysmo (Faricimab)

What It's For

Faricimab, sold as Vabysmo, is a prescription medicine injected into the eye to treat three conditions that damage the macula, the small central part of the retina responsible for sharp, straight-ahead vision used for reading, driving and recognizing faces. It is approved for adults with wet (neovascular) age-related macular degeneration, where abnormal blood vessels grow under the retina and leak fluid or blood. It also treats diabetic macular edema, swelling of the macula caused by leaky vessels in people with diabetes, and macular edema after a retinal vein occlusion, a blockage of one of the veins that drains blood from the retina. All three conditions can blur or distort central vision, and without treatment they can lead to lasting vision loss. Vabysmo belongs to the same broad family as other eye injections such as Eylea (aflibercept), which block a blood vessel growth signal called vascular endothelial growth factor (VEGF). In the main studies, Vabysmo protected vision about as well as Eylea, and its practical appeal is that some people can go longer between injections.

How It Works

VEGF-A (vascular endothelial growth factor A) is a signal that tells blood vessels to grow and become leaky. In these eye diseases, too much VEGF-A drives fragile new vessels and fluid buildup in the macula, which is what blurs vision. Faricimab is a lab-made antibody that latches onto VEGF-A and stops it from acting, so leakage and swelling settle and abnormal vessel growth slows. Faricimab is also bispecific, meaning one antibody grabs two targets. Its second target is angiopoietin-2 (Ang-2), a signal that makes blood vessels less stable and more sensitive to VEGF-A. Blocking Ang-2 is thought to help vessels stay calmer, which may be why some people can space injections further apart. The label notes, however, that how much the Ang-2 effect adds to the benefit has not yet been established.

Dosage & Administration

Vabysmo is given only by an eye specialist, as an injection into the vitreous, the gel that fills the back of the eye. The eye is numbed and cleaned with an antiseptic first, and the injection itself takes a few seconds. Each dose is the same small amount (6 mg); what varies is how often it is given. Treatment usually starts with monthly injections, typically four of them for wet macular degeneration and at least four for diabetic macular edema. After that, the specialist uses vision checks and optical coherence tomography (OCT), a quick, painless scan that shows fluid and thickness in the retina, to decide how far apart the next injections can be. For wet macular degeneration and diabetic macular edema, many people move to every two, three or four months, while others need to stay on monthly doses to keep the fluid controlled. For macular edema after a retinal vein occlusion, the label calls for monthly injections; in the studies, people received them for six months. Vision is often blurry for a while after the injection and the pupil-dilating drops used for the exam, so plan for someone else to drive you home. Do not drive or use machinery until your vision has recovered. Keeping appointments matters, because a missed or delayed injection can allow fluid to return.

Side Effects

Many people notice a small red patch on the white of the eye where the needle went in. This is a minor bleed under the eye's surface and usually fades over a week or two. Mild soreness, a gritty feeling, watering, new floaters (small specks drifting across vision) and a brief rise in eye pressure right after the injection are also common. Over longer courses, cataract (clouding of the lens) was reported more often in people treated for diabetic macular edema, at a rate similar to Eylea. Less commonly, an injection can lead to a serious problem: an infection inside the eye (endophthalmitis), a retinal tear or detachment, inflammation inside the eye, or retinal vasculitis, an inflammation of the retina's blood vessels that can block them and threaten vision. These usually show up in the days after an injection. If the treated eye becomes increasingly red, painful or sensitive to light, or your vision changes or worsens, contact your eye specialist right away so you can be seen the same day. Early treatment can make a real difference to how much vision is saved.

Interactions & Warnings

Vabysmo is not given when there is an infection in or around the eye, active inflammation inside the eye, or a known allergy to faricimab. Tell your specialist if your eye or eyelid is red, swollen or sore before an appointment, because the injection may need to be postponed. The prescribing information lists no specific drug interactions, but the eye team should still know your other medicines and your general health, including any past heart attack or stroke. Medicines that block VEGF carry a potential risk of blood clot events such as stroke or heart attack. In the studies these were uncommon and occurred at similar rates with Vabysmo and Eylea. Vabysmo has not been well studied in pregnancy, and animal studies and the way it works suggest a possible risk to a developing baby and to fertility. It should be used during pregnancy only if the benefit clearly outweighs the risk. People who could become pregnant are advised to use effective birth control before the first dose, during treatment and for at least three months after the last dose. It is not known whether faricimab passes into breast milk, so discuss breastfeeding plans with your specialist. It has not been studied in children.

What to Expect

Vabysmo is usually a long-term treatment. It controls leakage and swelling rather than curing the underlying disease, so the aim is to keep vision stable and, for many people, regain some of what was lost. In the studies of macular edema after a retinal vein occlusion, average vision improved by about three lines on the eye chart over six months of monthly injections. Results vary from person to person and depend on how much damage was present before treatment started. The first few months involve monthly visits. After that, the schedule depends on how your eye responds: each visit typically includes a vision test and an OCT scan, and the interval is stretched when the retina stays dry or shortened if fluid returns. Some people reach injections every three or four months, while others continue to need them more often. If Vabysmo is not controlling the fluid well enough, your specialist may shorten the interval or discuss other treatment options.

Questions to Ask Your Doctor

  1. 1.Why are you recommending Vabysmo for my eye rather than Eylea or another injection?
  2. 2.How will we decide how far apart my injections can be, and what would make us shorten the interval?
  3. 3.What changes in my vision should I realistically expect, and how will we measure them?
  4. 4.Which symptoms after an injection should make me call you right away, and how do I reach you after hours?
  5. 5.How long am I likely to need injections, and what happens to my vision if I stop or miss appointments?

Last reviewed • Oct 2026

Educational content, not medical advice.